CA-LINKSYS
Linksys®, an iconic Home and Small Office connectivity company, announces in a statement of direction its new Cognitive Experience technology. Cognitive Experience brings a whole new level of intelligence to networking with cutting-edge technological features specially designed to enhance and improve the user experience.
In the technology space, the word “cognitive” refers to “thinking technologies” that can deterministically – either by user selection or automation – solve problems. Developed based on user input and feedback, Cognitive Experience focuses on saving time and effort by automating the process for reporting technical issues to customer support agents.
“Currently 50% of our Support calls are dead air, nobody talking, as our Guardians review the logs and network information while the customer is on the phone,” said Lucas Peterson, Head of Product Support at Linksys. “With Linksys Cognitive Experience, we get all the information we need sent upfront through automation so that our Guardians can review and diagnose before they call the customer. This coupled with our ability to temporarily co-administer the network — with the customer’s permission, of course — will enable us to solve problems in lightning-fast time.”
Cognitive Experience allows a Linksys customer service agent to analyze your technical issue remotely, so that when they contact the user, they have all the information necessary to address the problem. Customer service agents can then administer tech support remotely through your network. You’re able to grant or rescind access to the network at any time. This allows customer service agents to effectively tackle any issues in lightning-fast time.
In Phase 1 of its implementation, Cognitive Experience features will focus on the following:
- If you experience a problem with your WiFi network, Cognitive Experience is able to run a test on your network
- Open a trouble-ticket from the Linksys App and get a call from Linksys customer service agents
- An agent will review the report and can easily access your network, with your permission, to address the problem
- Cognitive Experience will run a health check on your network to locate any additional potential issues
Phase 1 of Linksys Cognitive Experience is set to be completed by the end of this calendar year. Cognitive Experience will make its debut with products in the Linksys Designer Series through the end of the year. Starting in 2024, Cognitive Experience will be available in other Linksys products.
Phase 2 of Linksys Cognitive Experience is currently under development and includes new “intelligent notifications” that humanize or personalize the insights derived from your network, delivered in a meaningful way.
Examples of intelligent notifications include:
- When a network’s WAN goes down, we verify the Home Network is operating and then send a WAN Down notification
- When a network’s WAN comes back up, we verify it and retest the Home Network and send WAN Up and Home Network Up notifications
- Users can select certain devices to be notified when they leave and rejoin the network
Designer Series offerings that include Cognitive Experience are:
- Velop Pro 6E – currently available in the US at Amazon, Best Buy and Linksys.com
- Velop Pro 7 – expected in September/October, now available for pre order at Amazon and Best Buy
- Velop Micro Router 6 – expected in October/November
- Velop Micro Mesh 6 – expected in October/November
About Linksys
At Linksys, we engineer simplicity so that you never experience complexity. Linksys is an iconic brand celebrating its 35th year of innovation in Home and Small Office connectivity. With many industry firsts to its credit, Linksys delivers simple, fast, reliable, and affordable products for the Home and Small Office where there is “no IT.”
© 2023 Linksys Holdings, Inc. and/or its affiliates. All rights reserved.
Linksys and many product names and logos are trademarks of Linksys Holdings Inc. and/or its affiliates. Third-party trademarks mentioned are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913706425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom